About: Bradanicline

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Bradanicline Goto Sponge NotDistinct Permalink

An Entity of Type : yago:WikicatPyridines, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/c/9ug3q1QvqG

Bradanicline (INN, code name TC-5619) is a drug which was being developed by that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.

Attributes	Values
rdf:type	Thing dul:ChemicalObject chemical substance Drug yago:WikicatAmides yago:WikicatBenzofurans yago:WikicatStimulants yago:Abstraction100002137 yago:Amide114724264 yago:Base114618253 yago:Benzofuran114898101 yago:Chemical114806838 yago:Cognition100023271 yago:Compound114818238 yago:Information105816287 yago:Material114580897 yago:Matter100020827 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:PsychologicalFeature100023100 yago:Pyridine114692510 yago:Relation100031921 drug yago:Stimulation105827684 yago:Substance100019613 yago:WikicatPyridines
rdfs:label	Bradanicline (en)
rdfs:comment	Bradanicline (INN, code name TC-5619) is a drug which was being developed by that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials. (en)
foaf:depiction
dct:subject	Stimulants 3-Pyridyl compounds Antipsychotics AstraZeneca brands Nicotinic agonists Quinuclidines Benzofuran-2-carboxamides
Wikipage page ID	19476092 (xsd:integer)
Wikipage revision ID	1120547348 (xsd:integer)
Link from a Wikipage to another Wikipage	Schizophrenia Partial agonist International nonproprietary name Stimulants Clinical trials 3-Pyridyl compounds Antipsychotics Drug development Alpha-7 nicotinic receptor Alzheimer's disease AstraZeneca brands Nicotinic agonists AstraZeneca Quinuclidines Benzofuran-2-carboxamides Nicotinic acetylcholine receptor Attention deficit disorder dbr:Targacept
sameAs	Bradanicline Bradanicline Bradanicline Bradanicline Bradanicline Bradanicline
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Short_description dbt:Stimulants dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Nicotinic_acetylcholine_receptor_modulators
thumbnail	wiki-commons:Special:FilePath/Bradanicline_structure.svg?width=300
ATC suffix	None (en)
c	22 (xsd:integer)
CAS number	639489 (xsd:integer)
ChEMBL	1258006 (xsd:integer)
H	23 (xsd:integer)
IUPAC name	N-[-2--1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide (en)
KEGG	D10613 (en)
n	3 (xsd:integer)
O	2 (xsd:integer)
PubChem	16727410 (xsd:integer)
SMILES	C1CN2CCC1[C@@H]NCC4=CC5=CC=CC=C5O4 (en)
synonyms	TC-5619 (en)
UNII	UM3821998K (en)
verifiedrevid	444128206 (xsd:integer)
has abstract	Bradanicline (INN, code name TC-5619) is a drug which was being developed by that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials. In May 2011, AstraZeneca declined to exercise its right to license the compound. In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults. It was being studied for cognitive and memory enhancement. Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013. It was also discontinued for ADHD. (en)
gold:hypernym	Drug
prov:wasDerivedFrom	wikipedia-en:Bradanicline?oldid=1120547348&ns=0
page length (characters) of wiki page	3825 (xsd:nonNegativeInteger)
CAS number	639489-84-2
ChEMBL	1258006
FDA UNII code	UM3821998K
KEGG	D10613
PubChem	16727410
foaf:isPrimaryTopicOf	wikipedia-en:Bradanicline
is Link from a Wikipage to another Wikipage of	List of investigational attention deficit hyperactivity disorder drugs Encenicline TC-5619

Faceted Search & Find service v1.17_git147 as of Sep 06 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3332 as of Dec 5 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 54 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software